Timing of Onset of Garadacimab for Preventing Hereditary
Angioedema Attacks

J 2024

Timing of Onset of Garadacimab for Preventing Hereditary Angioedema Attacks

STAUBACH, Petra; Raffi TACHDJIAN; H. Henry LI; Roman HAKL; Emel AYGÖREN-PÜRSÜN et al.

Základní údaje

Originální název

Timing of Onset of Garadacimab for Preventing Hereditary Angioedema Attacks

Autoři

STAUBACH, Petra; Raffi TACHDJIAN; H. Henry LI; Roman HAKL; Emel AYGÖREN-PÜRSÜN; Lolis WIEMAN; Lawo JOHN-PHILIP a Timothy J. CRAIG

Vydání

Clinical & Experimental Allergy, Hoboken, Wiley, 2024, 0954-7894

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30225 Allergy

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 5.200

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/24:00137269

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

hereditary angioedema; garadacimab; attack prevention; treatment timing; clinical study

Štítky

14110114, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 30. 1. 2025 14:59, Mgr. Tereza Miškechová

Anotace

V originále

Hereditary angioedema (HAE) is a rare, autosomal dominant disease characterised by recurrent, unpredictable, painful, debilitating and potentially life-threatening attacks. HAE imparts a substantial disease burden that impacts daily activities and extends beyond symptoms directly attributable to HAE attacks, encompassing mental health (anxiety and depression) and psychosocial impacts associated with unpredictable attack recurrence.

Citovat

STAUBACH, Petra; Raffi TACHDJIAN; H. Henry LI; Roman HAKL; Emel AYGÖREN-PÜRSÜN; Lolis WIEMAN; Lawo JOHN-PHILIP a Timothy J. CRAIG. Timing of Onset of Garadacimab for Preventing Hereditary Angioedema Attacks. Clinical & Experimental Allergy. Hoboken: Wiley, 2024, roč. 54, č. 12, s. 1020-1023. ISSN 0954-7894. Dostupné z: https://doi.org/10.1111/cea.14568.

@article{2439817,
   author = {Staubach, Petra and Tachdjian, Raffi and Li, H. Henry and Hakl, Roman and AygörenandPürsün, Emel and Wieman, Lolis and JohnandPhilip, Lawo and Craig, Timothy J.},
   article_location = {Hoboken},
   article_number = {12},
   doi = {https://doi.org/10.1111/cea.14568},
   keywords = {hereditary angioedema; garadacimab; attack prevention; treatment timing; clinical study},
   language = {eng},
   issn = {0954-7894},
   journal = {Clinical & Experimental Allergy},
   title = {Timing of Onset of Garadacimab for Preventing Hereditary Angioedema Attacks},
   url = {https://onlinelibrary.wiley.com/journal/13652222},
   volume = {54},
   year = {2024}
}

TY  - JOUR
ID  - 2439817
AU  - Staubach, Petra - Tachdjian, Raffi - Li, H. Henry - Hakl, Roman - Aygören-Pürsün, Emel - Wieman, Lolis - John-Philip, Lawo - Craig, Timothy J.
PY  - 2024
TI  - Timing of Onset of Garadacimab for Preventing Hereditary Angioedema Attacks
JF  - Clinical & Experimental Allergy
VL  - 54
IS  - 12
SP  - 1020-1023
EP  - 1020-1023
PB  - Wiley
SN  - 09547894
KW  - hereditary angioedema
KW  - garadacimab
KW  - attack prevention
KW  - treatment timing
KW  - clinical study
UR  - https://onlinelibrary.wiley.com/journal/13652222
N2  - Hereditary angioedema (HAE) is a rare, autosomal dominant disease characterised by recurrent, unpredictable, painful, debilitating and potentially life-threatening attacks. HAE imparts a substantial disease burden that impacts daily activities and extends beyond symptoms directly attributable to HAE attacks, encompassing mental health (anxiety and depression) and psychosocial impacts associated with unpredictable attack recurrence.
ER  -

STAUBACH, Petra; Raffi TACHDJIAN; H. Henry LI; Roman HAKL; Emel AYGÖREN-PÜRSÜN; Lolis WIEMAN; Lawo JOHN-PHILIP a Timothy J. CRAIG. Timing of Onset of Garadacimab for Preventing Hereditary Angioedema Attacks. \textit{Clinical \&{} Experimental Allergy}. Hoboken: Wiley, 2024, roč.~54, č.~12, s.~1020-1023. ISSN~0954-7894. Dostupné z: https://doi.org/10.1111/cea.14568.

Přehled o publikaci